Economic impact of gefitinib for refractory non-small-cell lung cancer: a Markov model-based analysis

References

• Goodwin PJ, Shepherd FA. Economic issues in lung cancer: a review. J Clin Oncol 1998;16:3900–12
   PubMed Web of Science ®Google Scholar
• Kutikova L, Bowman L, Chang S, et al. The economic burden of lung cancer and the associated costs of treatment failure in the United States. Lung Cancer 2005;50:143–54
   PubMed Web of Science ®Google Scholar
• Ettinger D, Johnson B. Update: NCCN small cell and non-small cell lung cancer Clinical Practice Guidelines. J Natl Compr Canc Netw 2005;3:S17–21
   PubMedGoogle Scholar
• De Petris L, Crino L, Scagliotti GV, et al. Treatment of advanced non-small cell lung cancer. Ann Oncol 2006;17: ii36–41
   Google Scholar
• Shepherd FA. Second-line chemotherapy for non-small cell lung cancer. Expert Rev Anticancer Ther 2003;3:435–42
   PubMedGoogle Scholar
• Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589–97
   PubMed Web of Science ®Google Scholar
• De Marinis F, De Petris L. Pemetrexed in second-line treatment of non-small-cell lung cancer. Oncology (Williston Park) 2004;18:38–42
   PubMedGoogle Scholar
• Raben D, Helfrich B, Ciardiello F, et al. Understanding the mechanisms of action of EGFR inhibitors in NSCLC: what we know and what we do not know. Lung Cancer 2003;41: S15–22
   PubMedGoogle Scholar
• Buter J, Giaccone G. EGFR inhibitors in lung cancer. Oncology (Williston Park). 2005;19:1707–11
   PubMed Web of Science ®Google Scholar
• Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21:2237–46
   PubMed Web of Science ®Google Scholar
• Fujiwara K, Kiura K, Ueoka H, et al. Dramatic effect of ZD1839 (‘Iressa’) in a patient with advanced non-small-cell lung cancer and poor performance status. Lung Cancer 2003;40:73–6
   PubMed Web of Science ®Google Scholar
• Cella D. Impact of ZD1839 on non-small cell lung cancer-related symptoms as measured by the functional assessment of cancer therapy-lung scale. Semin Oncol 2003;30:39–48
   PubMed Web of Science ®Google Scholar
• Janne PA, Gurubhagavatula S, Yeap BY, et al. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, ‘Iressa’) on an expanded access study. Lung Cancer 2004;44:221–30
   PubMed Web of Science ®Google Scholar
• LoRusso PM, Herbst RS, Rischin D, et al. Improvements in Quality of Life and Disease-related Symptoms in Phase I Trials of the Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 in Non-Small Cell Lung Cancer and Other Solid Tumors. Clin Cancer Res 2003;9:2040–8
   PubMed Web of Science ®Google Scholar
• Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527–37
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Rodrigues Pereira J, et al. National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353: 123–32
   PubMed Web of Science ®Google Scholar
• Leighl NB, Tsao WS, Zawisza DL, et al. Willingness-topay study of oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small cell lung cancer. Lung Cancer 2006;51:115–21
   PubMed Web of Science ®Google Scholar
• Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993;13:322–8
   PubMed Web of Science ®Google Scholar
• Desky AS, Naglie IG. A clinician’s guide to cost-effectiveness analysis. Ann Intern Med 1990;113:147–54
   PubMed Web of Science ®Google Scholar
• van Puijenbroek R, Bosquee L, Meert AP, et al. Gefitinib mono-therapy in advanced nonsmall cell lung cancer: a large Western community implementation study. Eur Respir J 2007;29: 128–33
   PubMed Web of Science ®Google Scholar
• Ramsey SD, Howlader N, Etzioni RD, et al. Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from surveillance, epidemiology and end results-Medicare. J Clin Oncol 2004;22:4971–8
   PubMed Web of Science ®Google Scholar
• Chouaid C, Molinier L, Combescure C, et al. Economics of the clinical management of lung cancer in France: an analysis using a Markov model. Br J Cancer 2004;90:397–402
   PubMed Web of Science ®Google Scholar
• Dedes KJ, Szucs TD, Bodis S, et al. Management and costs of treating lung cancer patients in a university hospital. Pharmaco-economics 2004;22:435–44
   Google Scholar
• Braud AC, Levy-Piedbois C, Piedbois P, et al. Direct treatment costs for patients with lung cancer from first recurrence to death in France. Pharmacoeconomics 2003;21:671–9
   PubMed Web of Science ®Google Scholar
• Spiro SG, Rudd RM, Souhami RL, et al. Big Lung Trial participants. Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax 2004;59:828–36
   Google Scholar
• Berthelot JM, Will BP, Evans WK, et al. Decision framework for chemotherapeutic interventions for metastatic non-small-cell lung cancer. J Natl Cancer Inst 2000;92:1321–9
   PubMed Web of Science ®Google Scholar
• Earle CC, Evans WK. Cost-effectiveness of paclitaxel plus cisplatin in advanced non-small-cell lung cancer. Br J Cancer 1999;80: 815–20
   PubMed Web of Science ®Google Scholar
• Leighl NB, Shepherd FA, Kwong R, et al. Economic analysis of the TAX 317 trial: docetaxel versus best supportive care as second-line therapy of advanced non-small-cell lung cancer. J Clin Oncol 2002;20:1344–52
   PubMed Web of Science ®Google Scholar
• Holmes J, Dunlop D, Hemmett L, et al. A cost-effectiveness analysis of docetaxel in the second-line treatment of non-small cell lung cancer. Pharmacoeconomics 2004;22:581–9
   PubMed Web of Science ®Google Scholar
• Côté I, Leighl NB, Gyldmark M, Maturi B. Pharmacoeconomic analyses of erlotinib compared with best supportive care (BSC) for the treatment of relapsed non-small cell lung cancer (NSCLC) from the Canadian public health care perspective. Value Health 2006;6:A279
   Google Scholar
• Lewis G, Morlotti L, Creeden J, et al. Cost-effectiveness of erlotinib compared with docetaxel for the treatment of relapsed non small cell lung cancer (SNCL) in UK. Value Health 2006;6: A203
   Google Scholar